MK-7009: this is a potent molecule, hybridized from all that's come before it. We'll need to wait to hear more on liver concentration and other PK, but they've had plenty of time to study those who came to the table early...should make for a great story at the end of the day.
>> Isis Receives $1 Million Milestone Payment From Merck on Initiation of Clinical Development of a Compound Discovered in a Collaboration Between the Companies
CARLSBAD, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Merck & Co., Inc. has initiated clinical development of a compound that was discovered as part of a funded research collaboration between Merck and Isis scientists. Merck will pay Isis a $1 million milestone payment based on the initiation of clinical trials.
Isis' Senior Vice President of Research, C. Frank Bennett, Ph.D., commented, "We're pleased to see Merck advancing this molecule in clinical trials. The compound was created out of our productive collaboration which took advantage of Isis' expertise in nucleic acid therapeutics. We look forward to Merck's future progress with this compound." <<
This was an unusually uninformative communique due, undoubtedly, to Merckian influence. Speculation was that the partnered drug was MK-7009, but it turns out MK-0608, a nucleoside polymerase inhibitor, is the collaborative compound. I have no idea regarding its chances of success.
Market Data 
Markets 
AI
